# Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Source: https://onco.cc/trials/nct02793583/  
OnCo record `nct02793583` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Umbralisib and Bendamustine in Diffuse large B-cell lymphoma, Follicular lymphoma, Marginal zone lymphoma and Mantle cell lymphoma, run by TG Therapeutics, Inc., recorded as terminated on the registry.

## Summary

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma is a phase 2/3 interventional study registered as NCT02793583 by TG Therapeutics, Inc., with 710 participants recorded, started 2016-05-25 and due to reach its primary completion in 2022-05-31. Interventions recorded: Ublituximab, Umbralisib, Bendamustine. Conditions recorded: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma.

Linked to the drug Umbralisib because the registry names it among its interventions and Diffuse large B-cell lymphoma, Follicular lymphoma, Marginal zone lymphoma and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02793583
- Phase: 2/3
- Setting: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma
- Sponsor: TG Therapeutics, Inc.
- Enrolled: 710

## Sources

- ClinicalTrials.gov NCT02793583: https://clinicaltrials.gov/study/NCT02793583

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Umbralisib](https://onco.cc/drugs/umbralisib/)

---
JSON: https://onco.cc/api/v1/entities/nct02793583.json